Trial
NCT00905398
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Rony Schaffel
Collaborators
—
Condition
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Intervention
Nilotinib
Why stopped
The study was terminated due to excessive toxicity and low compliance to the protocol scheme.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-07-09